The institutional investor owned 186,168 shares of the biopharmaceutical company’s stock after purchasing an additional 15,957 shares during the period. Columbia Asset Management’s holdings in Pfizer were worth $4,513,000 at the end of the most recent quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after acquiring an additional 838,198 shares during the period.